Company profile
Dakshidin Corporation
OTC: DKSC · Healthcare · Drug Manufacturers - Specialty & Generic
#1161 of 1,418 Healthcare companies by revenue
EA Score
31DFH 36DQ —GM 6SS 52
v0.1 · 45/100 weight · provisional
↑ return on assets, listing tenure · ↓ 3-yr revenue growth, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$41.3k
Employees
—
as of 2026-08-25
Market cap
$1.8M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$41.3k-$41.3k2025
Operating income-$41.3k-$41.3k2025
Total assets$415.5k$415.5k2023
Liabilities$408.7k$408.7k2023
Equity$6.8k$6.8k2023
Revenue trend
FY2017 – FY2025 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Dakshidin Corporation’s revenue?
Dakshidin Corporation booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
iMD Companies, Inc.47DTelo Genomics Corp.——Lobe Sciences Ltd.42DDecoy Therapeutics Inc.31DProtagenic Therapeutics, Inc.——Welsis Corp.20DNeighbors
Miami-Dade →Key facts
CEOChristopher Robin Haigh
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMiami, FL
ExchangeOTC: DKSC
Employees—
IPO date2009-09-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.